Clinical trial
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
NCT00460551 · Genmab, Industry · Terminated
Key facts
| NCT number | NCT00460551 |
|---|---|
| Title | Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer |
| Official title | A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients |
| Lead sponsor | Genmab, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | Zalutumumab, Induction chemotherapy, Radiotherapy |
| Enrollment | 13 |
| Start date | Apr 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Apr 16, 2007 |
| Last update posted | Dec 6, 2011 |
| Countries | Belgium, France, Netherlands, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: